Acorda Therapeutics Cdt Stock
Pros and Cons of Acorda Therapeutics Cdt in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acorda Therapeutics Cdt vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Acorda Therapeutics Cdt | - | - | - | - | - | - | - |
Ardelyx Inc. | -0.830% | -0.416% | 17.913% | 119.146% | 24.360% | 27.221% | - |
Evolus Inc | 5.130% | 4.237% | 16.038% | 36.667% | 35.912% | 72.028% | - |
Salarius Pharmaceuticals Inc. | 7.850% | -5.069% | -1.905% | -64.174% | -25.766% | -98.542% | -99.992% |
Comments
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat